Jan Haussmann1, Christiane Matuschek, Edwin Bölke, Klaus Orth, Pirus Ghadjar, Wilfried Budach. 1. Department of Radiation Oncology, Düsseldorf University Hospital, Heinrich-Heine-Universität Düsseldorf; Goslar: Prof. Dr. med. Klaus Orth (formerly: Department of General, Visceral and Thoracic Surgery, Asklepios Harzkliniken Goslar); Department of Radiation Oncology and Radiotherapy, Charité-Universitätsmedizin Berlin.
Abstract
BACKGROUND: Systemic treatment is standard for most types of cancer with disseminated metastases. The role of local treatment (LT) of individual tumor foci in patients with oligometastatic disease is unclear and the object of current scientific studies. METHODS: This review is based on pertinent publications retrieved by a selective search in PubMed. RESULTS: Four randomized trials have shown that radical local treatment confers an advantage with respect to overall survival (OS), compared to systemic treatment alone, in patients with oligometastatic disease. In patients with synchronous metastases and a stable primary tumor, LT prolongs the median overall survival by approximately two years. A single randomized trial for oligometastatic small-cell lung cancer did not show any prolongation of overall survival. Local treatment increased the frequency of grade III side effects by approximately 10%. CONCLUSION: Although local treatment already has a place in many guidelines on the basis of the findings of a small number of prospective and retrospective studies, a option of local treatment should be considered by an interdisciplinary tumor board individually for suitable patients.
BACKGROUND: Systemic treatment is standard for most types of cancer with disseminated metastases. The role of local treatment (LT) of individual tumor foci in patients with oligometastatic disease is unclear and the object of current scientific studies. METHODS: This review is based on pertinent publications retrieved by a selective search in PubMed. RESULTS: Four randomized trials have shown that radical local treatment confers an advantage with respect to overall survival (OS), compared to systemic treatment alone, in patients with oligometastatic disease. In patients with synchronous metastases and a stable primary tumor, LT prolongs the median overall survival by approximately two years. A single randomized trial for oligometastatic small-cell lung cancer did not show any prolongation of overall survival. Local treatment increased the frequency of grade III side effects by approximately 10%. CONCLUSION: Although local treatment already has a place in many guidelines on the basis of the findings of a small number of prospective and retrospective studies, a option of local treatment should be considered by an interdisciplinary tumor board individually for suitable patients.
Authors: Oscar Arrieta; Feliciano Barrón; Federico Maldonado; Luis Cabrera; José Francisco Corona-Cruz; Monika Blake; Laura Alejandra Ramírez-Tirado; Zyanya Lucia Zatarain-Barrón; Andrés F Cardona; Osvaldo García; Osvaldo Arén; Jaime De la Garza Journal: Lung Cancer Date: 2019-02-07 Impact factor: 5.705
Authors: Joe Y Chang; Suresh Senan; Marinus A Paul; Reza J Mehran; Alexander V Louie; Peter Balter; Harry J M Groen; Stephen E McRae; Joachim Widder; Lei Feng; Ben E E M van den Borne; Mark F Munsell; Coen Hurkmans; Donald A Berry; Erik van Werkhoven; John J Kresl; Anne-Marie Dingemans; Omar Dawood; Cornelis J A Haasbeek; Larry S Carpenter; Katrien De Jaeger; Ritsuko Komaki; Ben J Slotman; Egbert F Smit; Jack A Roth Journal: Lancet Oncol Date: 2015-05-13 Impact factor: 41.316
Authors: Elizabeth M Gore; Chen Hu; Alexander Y Sun; Daniel F Grimm; Suresh S Ramalingam; Neal E Dunlap; Kristin A Higgins; Maria Werner-Wasik; Aaron M Allen; Puneeth Iyengar; Gregory M M Videtic; Russell K Hales; Ronald C McGarry; James J Urbanic; Anthony T Pu; Candice A Johnstone; Volker W Stieber; Rebecca Paulus; Jeffrey D Bradley Journal: J Thorac Oncol Date: 2017-06-23 Impact factor: 15.609
Authors: W Jeffrey Petty; James J Urbanic; Tamjeed Ahmed; Ryan Hughes; Beverly Levine; Kyle Rusthoven; Michael Papagikos; Jimmy R Ruiz; Brian E Lally; Michael Chan; Hollins Clark; Ralph B D'Agostino; A William Blackstock Journal: Int J Radiat Oncol Biol Phys Date: 2018-07-10 Impact factor: 7.038
Authors: Neil Mehta; Ann M Mauer; Samuel Hellman; Daniel J Haraf; Ezra E W Cohen; Everett E Vokes; Ralph R Weichselbaum Journal: Int J Oncol Date: 2004-12 Impact factor: 5.650
Authors: Annkathrin Hanssen; Carlotta Riebensahm; Malte Mohme; Simon A Joosse; Janna-Lisa Velthaus; Lars Arne Berger; Christian Bernreuther; Markus Glatzel; Sonja Loges; Katrin Lamszus; Manfred Westphal; Sabine Riethdorf; Klaus Pantel; Harriet Wikman Journal: Cancers (Basel) Date: 2018-12-19 Impact factor: 6.639
Authors: M Michl; F Taverna; J Kumbrink; T S Schiergens; V Heinemann; J Engel; T Kirchner; Jens Neumann Journal: Virchows Arch Date: 2020-12-09 Impact factor: 4.064